Articles Vol. 67 No. 6 25/06/2026

LINICAL, SUBCLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH TALAROMYCES MARNEFFEI INFECTION AT THE NATIONAL

Nguyen Ngoc Truong Thi1,2, Nguyen Ngoc Truong Thi1,2, Tran Thanh Cuong1,2
1 National Lung Hospital
2 Bệnh viện Phổi Trung ương
DOI: 10.52163/yhc.v67i6.5545
27 Views
16 Downloads
Keywords
t antifungal intervention. Keywords:
Abstract

Introduction

Talaromyces marneffei formerly known as Penicillium marneffei, is the only dimorphic fungus within the Talaromyces genus capable of causing systemic mycosis in humans, significantly contributing to mortality among HIV/AIDS patients. Due to its non-specific clinical and paraclinical manifestations, the disease is frequently misdiagnosed as other infectious pathologies, leading to delayed treatment and increased mortality rates.

Methods

A retrospective study was conducted on 30 patients diagnosed with Talaromyces marneffei infection and treated at the National Lung Hospital from January 2024 to September 2025. Subjects were divided into two groups: HIV-positive [HIV(+)] and HIV-negative [HIV(-)] to compare clinical characteristics, laboratory findings, and mortality rates.

Results

The HIV(+) group (n=9) was significantly younger than the HIV(-) group (38,44 ± 10,0 vs. 55,29 ± 12,7 years; p = 0,002). Clinically, HIV(+) patients exhibited a markedly higher prevalence of diarrhea (77,8%), umbilicated skin papules (77,8%)  and splenomegaly (33,3%) compared to the HIV(-) group (p < 0,05). Regarding laboratory findings, no statistically significant differences were found between the two groups ( p > 0,05). However, the HIV(+) group showed a trend toward lower white blood cell counts ( 8,1 ± 7,4 G/L vs. 15,0 ± 9,6 G/L; p = 0,064). The overall mortality rate was 23,3%, with the HIV(+) group showing a higher trend compared to the HIV(-) group ( 33,3% vs. 19,0% ; p > 0,05).

Disscusion and Conclusion

Clinical manifestations of Talaromyces marnerffei infection differ significantly between the two groups. HIV(+) patients typically present with a robust systemic disease including skin papules, diarrhea, and organ involvement (liver, spleen). Conversely, the HIV(-) group predominantly exhibits respiratory symptoms, often mimicking pulmonary tuberculosis or respiratory diseases. High mortality rates in both groups, particularly in HIV(+) patients, underscore the critical importance of early diagnosis and prompt antifungal intervention.

References
[1]
S. Narayanasamy, V. Q. Dat, N. T. Thanh và cộng sự (2021). A global call for talaromycosis to be recognised as a neglected tropical disease. The Lancet Global Health, 9 (11), e1618-e1622. doi: 10.1016/S2214-109X(21)00350-8. Google Scholar
[2]
Võ Triều Lý, Vương Minh Nhựt, Thuỳ Lê (2023). Tổng quan về nhiễm nấm talaramoyces marneffei ở người bệnh nhiễm HIV/AIDS. Tạp chí Y học Việt Nam, 1, 145-150. Google Scholar
[3]
Bộ Y tế (2021). Hướng dẫn chẩn đoán và điều trị nhiễm nấm xâm lấn. Quyết định 3429/QĐ-BYT, Google Scholar
[4]
Thuy Le M. W., Nguyen Huu Chi, Vo Minh Quang, Nguyen Tran Chinh, Nguyen Phu Huong Lan, Pham Si Lam, Michael J. Kozal, Cecilia M. Shikuma, Jeremy N. Day and Jeremy Farrar (2011). Epidemiology, Seasonality, and Predictors of Outcome of AIDS-Associated Penicillium marneffei Infection in Ho Chi Minh City, Viet Nam. . Clin Infect Dis, 52 (7), 945-952. doi: 10.1093/cid/cir028. Google Scholar
[5]
Phạm Thị Vân Anh, Hoàng Thị Hà (2015). Đặc điểm lâm sàng và kết quả điều trị ban đầu nhiễm nấm penicillum marneffei trên người bệnh nhiễm HIV/AIDS tại Bệnh viện Việt Tiệp, Hải Phòng từ 2008-2014. Truyền nhiễm Việt Nam, 1, 60-65. Google Scholar
[6]
R. Kawila, R. Chaiwarith và K. Supparatpinyo (2013). Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis, 13, 464. doi: 10.1186/1471-2334-13-464. Google Scholar